Primed Microglia plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000129 | microglial cell |
| Database | ID | Name | Confidence | [1]
|----------|----|------|------------| [2]
| Cell Ontology | CL:0000129 | microglial cell | Medium | [3]
Primed microglia represent a critical intermediate activation state in the spectrum of microglial phenotypes, situated between the surveilling "resting" state and the fully activated pro-inflammatory (M1-like) phenotype. This primed state is characterized by an elevated inflammatory baseline with enhanced responsiveness to secondary stimuli, making these cells particularly relevant in the context of aging and neurodegenerative diseases. Understanding primed microglia is essential for unraveling the complex neuroimmune interactions that underlie conditions such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). [4]
The concept of microglial priming emerged from observations that the aging brain and chronic neurodegenerative conditions sensitize microglia, creating a pre-conditioned state where these cells respond more dramatically to minor inflammatory challenges. This priming phenomenon explains why elderly individuals and patients with neurodegenerative diseases often exhibit exaggerated neuroinflammatory responses to infections, surgeries, or minor injuries—a phenomenon known as "inflammaging." [5]
Microglia originate from embryonic yolk sac progenitors during early development, representing the only CNS cell population derived from a distinct embryonic source: [6]
Developmental Timeline: [7]
Self-Renewal and Homeostasis: [8]
Species Differences:
Resting (surveilling) microglia in the healthy brain are far from inactive:
Morphological Characteristics:
Functional Properties:
Molecular Profile:
Primed microglia occupy a transitional position in the microglial activation spectrum:
Core Characteristics:
The "Second Hit" Hypothesis:
The priming concept explains why aged or diseased brains exhibit exaggerated neuroinflammatory responses:
Surface Marker Expression:
| Marker | Resting | Primed | Significance |
|---|---|---|---|
| MHC-II (HLA-DR) | Low | Moderate-High | Antigen presentation |
| CD68 | Low | Moderate-High | Phagocytic activity |
| CD86 | Low | Moderate | Co-stimulation |
| C3 | Low | High | Complement, astrocyte signaling |
| TREM2 | Moderate | Variable | Depends on context |
| CD40 | Low | Moderate | T-cell interaction |
Transcriptomic Profile:
Upregulated genes in primed microglia:
Downregulated genes:
Proteomic Changes:
Multiple pathways contribute to microglial priming:
Aging-associated changes:
Chronic neurodegeneration:
Environmental exposures:
Genetic factors:
While microglia are not traditionally considered electrically excitable, they express various ion channels:
Potassium Channels:
Calcium Channels:
Functional Significance:
Primed microglia show altered electrophysiological properties:
Primed microglia play a central role in AD pathogenesis:
Pathological Contributions:
Amyloid-β response:
Tau pathology propagation:
Synaptic loss:
Molecular Mechanisms:
Therapeutic Implications:
Primed microglia contribute to PD progression:
Key Features:
Mechanisms:
Microglial priming in ALS:
Motor Neuron Vulnerability:
Genetic Interactions:
Primed microglia in MS/EAE:
Demyelination:
Disease Progression:
Primed microglia generate detectable signatures:
Imaging:
Fluid Biomarkers:
Strategies targeting primed microglia:
| Approach | Mechanism | Status |
|---|---|---|
| TREM2 agonists | Enhance phagocytosis | Clinical trials |
| CSF1R antagonists | Reduce microglial numbers | Phase trials |
| Minocycline | Anti-inflammatory | Mixed results |
| NLRP3 inhibitors | Block inflammasome | Preclinical |
| Complement inhibitors | Block synaptic pruning | Preclinical |
| Microglial repopulation | Replace dysfunctional cells | Experimental |
Microglial priming influences:
In vitro systems:
In vivo models:
Current research directions:
The aging brain provides a natural priming model:
Age-Associated Changes:
Functional Consequences:
Primed Microglia plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Primed Microglia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Heneka MT, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015. 2015. ↩︎
Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol. 2017. 2017. ↩︎
Sarlus H, Heneka MT. Microglia in Alzheimer's disease. J Clin Invest. 2017. 2017. ↩︎
Gao F, et al. Microglial activation and its implications in Parkinson's disease. J Neuroinflammation. 2023. 2023. ↩︎
Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017. 2017. ↩︎
Krasemann S, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017. 2017. ↩︎
Deczkowska A, et al. Disease-associated microglia: A universal immune sensor of neurodegeneration. Cell. 2018. 2018. ↩︎
Hansen DV, et al. Microglia in Alzheimer's disease. J Exp Med. 2018. 2018. ↩︎